Search results
Showing results for
Neutralising mAbs, a form of anti-viral medicine, are being explored as an attractive option to treat symptoms of COVID-19 and in some cases prevent infection. But what are the pros and cons of this type of treatment and what should regulators consider before granting approval?
Srinivasa Rao Rao
MBBS, MS (res), DPhil, AFHEA Srinivasa Rao Rao - Senior Researcher in Cancer Genomics
Matthew Costa
Matthew Costa - Professor of Orthopaedic Trauma Surgery
Jelena Bezbradica Mirkovic
PhD Jelena Bezbradica Mirkovic - Professor of Immunology
Antonella Delmestri
PhD Antonella Delmestri - Associate Professor of Health Data Science
Steve Gwilym
MBBS, BSc, DPhil, FRCS (Tr & Orth) Steve Gwilym - Associate Professor & Consultant Orthopaedic Surgeon
Dan Perry
MBChB (Hons), MA(Oxon), PhD, FHEA, FRCS (Orth), FRCSEd (Ad Hominem) Dan Perry - Honorary Professor, Children's Orthopaedics & Trauma Surgery
Liye Chen
MD PhD Liye Chen - Career Development Fellow - Arthritis UK
Graham Heieis
Graham Heieis - Postdoctoral Research Assistant in Mucosal Immunology
Jolet Mimpen
DPhil, MSc, BSc (Hons) Jolet Mimpen - Senior Research Fellow in Musculoskeletal Tissue Biology
Michael Dustin
Michael Dustin - Kennedy Trust Professor of Molecular Immunology
Sara Khalid
BE, MSc (Oxon), DPhil Sara Khalid - Associate Professor of Health Informatics and Biomedical Data Science
Beata Giglio
Beata Giglio - Programme Manager for Functional Genomics Cluster / Project Manager for Health Economics and Outcomes Research Group